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Case Report
Analysis of the Dilemma Involving Statins and Aspirin 
as Primary Prevention Alternatives in Cardiovascular 
Disease
Henry Sutanto
Cardiovascular disease is one of the deadliest diseases in the world. Nowadays, 
alongside the developments of various medical therapeutic strategies, there is 
a decreasing trend of cardiovascular mortality. However, this reduction is not 
adequate and needs to be supported by cardiovascular prevention approaches. 
Statins and aspirin are two of cardiovascular drugs that are believed to be beneficial 
in cardiovascular prevention. Their magnificent efficacies in the secondary 
prevention setting lead them to be used in the primary prevention. However, 
some safety issues associated with the drugs should be considered. For that 
reason, based on previous trials and studies, some recommendations regarding 
the efficacy-safety issues are developed. 
(J Kardiol Indones. 2017;38:38-48)
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Laporan Kasus
Penyakit kardiovaskular adalah salah satu penyakit dengan angka kematian tertinggi di dunia. Saat ini, seiring dengan 
perkembangan berbagai metode penatalaksanaan medis penyakit kardiovaskular, didapatkan penurunan angka kematian 
yang diakibatkan oleh penyakit-penyakit tersebut. Namun, penurunan ini belum adekuat dan masih membutuhkan upaya 
pencegahan penyakit kardiovaskular sebagai intervensi penunjang. Statin dan aspirin adalah dua jenis obat kardiovaskular 
yang diyakini memiliki efek farmakologis mumpuni dalam pencegahan penyakit kardiovaskular. Efikasi kedua obat tersebut 
dalam pencegahan sekunder mengarahkan penggunaannya dalam lingkup yang lebih luas, yakni pencegahan primer penyakit 
kardiovaskular. Namun, beberapa masalah keamanan obat sering ditemui dan harus diperhatikan dalam penggunaannya. 
Dengan alasan inilah, berdasarkan penelitian dan eksperimen terkini, rekomendasi mengenai penggunaan kedua obat tersebut 
untuk penyakit kardiovaskular saat ini sedang dikembangkan. 
(J Kardiol Indones. 2017;38:38-48)
Kata kunci: aspirin, statin, kardiovaskular, pencegahan
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Introduction
For many years, Cardiovascular Disease (CVD) has become a global burden and caused limitations in daily activities. It was the leading cause of death worldwide in 2013.1 
In the United Kingdom (UK), cardiovascular disease 
mortality was almost one-third of all-cause mortality 
across age and gender.2 In 2014, cardiovascular diseases 
stood below cancer as the most common cause of death 
in the UK (Figure 1).1,2 
Various medical therapeutics strategies in cardio-
vascular medicine had been developed to overcome 
this problem. However, those developments were 
not enough to tackle the problem and cardiovascular 
disease remained challenging. For that reason, a 
few years ago, cardiovascular disease prevention was 
proposed as one of the breakout solutions. Nowadays, 
cardiovascular disease prevention is believed to be one 
of the best approaches to tackle cardiovascular disease 
and its complications. 
Atherosclerotic CVD especially coronary artery 
disease is the deadliest of all cardiovascular disease group 
members.1 It comprises a broad spectrum of disease 
pathology and clinical feature, from asymptomatic 
fatty streak to deadly ruptured plaque. For many years, 
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Figure 1. A) All-cause mortality in the UK classified by gender (2014). Cancer is the deadliest disease in both sexes (male 
and female) followed by cardiovascular disease at the second place. B) The Age-standardised death rate of CVD in 1968-
2013. The mortality of CVD is decreasing with the improvement of CVD managements and prevention (cited from: 
Bhatnagar P, Wickramasinghe K, Williams J, et al. Heart. 2015;0:1-8 and Townsend N, Bhatnagar P, Wilkins E, et al. 
BHF. 2015).
A
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alongside the progression of therapeutic strategies 
developments, researchers and clinicians have tried 
to prevent this disease by modifying its risk factors. 
There are at least four major modifiable risk factors 
for Coronary Artery Disease (CAD), such as smoking, 
dyslipidemia, hypertension and diabetes mellitus. 
Furthermore, lifestyle modifications, such as exercise 
and healthy diet, are believed to be beneficial in tackling 
CAD. However, these lifestyle changes will not bring 
any favourable outcome unless there are interventions to 
those cardinal risk factors in the early stage of the disease. 
These interventions are not easy to be done because 
the initial stage of CAD and associated risk factors are 
usually asymptomatic and silent. For that reason, some 
experts recommend the use of several drugs, such as 
HMG-CoA Reductase Inhibitor (statin) and aspirin, 
as primary prevention modalities in Atherosclerotic 
Cardiovascular Disease (ASCVD), especially coronary 
artery disease. 
Overview of pharmacological aspects of 
statins and aspirin
Statin acts as an inhibitor of hydroxymethyl glutaryl-
CoA (HMG-CoA) reductase enzyme. Its role in the 
inhibition of sterol biosynthetic pathway makes statin 
a potent lipid-lowering drug. Statin is also proven to 
be beneficial in cardiovascular disease management 
and prevention. So far, statin family comprises of at 
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Figure 2. Plaque regression in an aortic atherosclerotic plaque 6-months after statin therapy. A) 
Reduction of the plaque volume B) Reduction of the plaque area C) Cellular pathway of plaque 
regression and stabilisation (cited from: Lima JAC, Desai MY, Steen H, et al. Circulation. 2004; 
110:2336-2341 and Dave T, Ezhilan J, Vasnawala H, et al. IJEM. 2013;17(6):983-9).32
Figure 2. Plaque regression in an aortic atherosclerotic plaque 6-months after statin therapy. A) 
Reduction of the plaque volume B) Reduction of the plaque area C) Cellular pathway of plaque 
regression and stabilisation (cited from: Lima JAC, Desai MY, Steen H, et al. Circulation. 2004; 
110:2336-2341 and Dave T, Ezhilan J, Vasnawala H, et al. IJEM. 2013;17(6):983-9).32
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least eight major members, including Pravastatin, 
Fluvastatin, Compactin, Atorvastatin, Lovastatin, 
Simvastatin, Pitavastatin, and Rosuvastatin.3
Those major types of statins have different 
potencies and characteristics depend on their 
molecular structures. Furthermore, they have different 
pharmacokinetic properties such as metabolism by 
cytochrome P-450, bioavailability, hydrophobicity, and 
cellular transport mechanisms. Despite the efficacy of 
statin in cardiovascular disease management, some side 
effects may appear, such as raised incidences of diabetes 
mellitus, ocular cataracts, a wide range of muscular 
disorders (from muscle pain to rhabdomyolysis). 
Additionally, some patients may also experience liver 
toxicity, proteinuria and haematuria as the effects of 
long-term statin therapy.3 
Besides statins, there is another cardiovascular drug 
that also provides enormous benefits in cardiovascular 
disease management. It is named acetylsalicylic acid 
or aspirin. It was originated from willow bark and 
it used to be an analgesic in an ancient era.4 Aspirin 
is categorised as a non-steroidal anti-inflammatory 
drug (NSAID). Now, it is occasionally used as an 
antipyretic drug, but the primary use of this drug is 
for cardiovascular disease. 
As a cardiovascular drug, aspirin plays a role in 
platelet physiology.5 Aspirin exerts its effect mainly 
by disrupting the biosynthesis of prostanoids, such as 
prostaglandin, prostacyclin and the most important 
one, Thromboxane A2 (TxA2).
4 Consequently, 
aspirin inhibits platelets aggregation that occurs 
during inflammation or haemostatic process.4 In 
prolonged use, aspirin can cause gastrointestinal 
side effects such as gastritis, peptic ulcer and gastric 
bleeding. Furthermore, the disruption of the 
haemostatic process increases the bleeding risk and 
potentially leads to haemorrhagic stroke or other 
complications.4 
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Figure 3. The result of ASCOT-LLA trial (11-year mortality follow-up). The effect of statin in the reduction of cardiovascular 
disease mortality is still present after 11 years (showed by reduction of all-cause and cardiovascular mortality – A&B). No 
increased cancer mortality due to statin administration (C) (cited from: Sever PS, Chang CL, Gupta AK, et al. European 
Heart Journal. 2011;-:1-8).
Roles of statins and aspirin in ASCVD 
management
Statins and aspirin are widely used as secondary 
prevention modalities in atherosclerotic cardiovascular 
diseases, especially coronary artery disease.6 They 
provide tremendous benefits to patients who suffered 
from CAD. Statins, for example, have roles in 
lowering LDL-cholesterols level in the bloodstream 
and increasing LDL-cholesterols uptake from an 
atherosclerotic plaque. As the result, lipid depositions 
inside the atheroma are reduced and the plaque is 
stabilised. Additionally, statins have some pleiotropic 
effects, such as inflammation reduction, endothelial 
function improvement and plaque regression effects 
(Figure 2).6-8 This plaque regression effect begins in 
the early phase of CAD and is associated with the 
reduction of the necrotic core.9 
The Scandinavian Simvastatin Survival Study 
(4S)10 reported a reduction in major cardiovascular 
events and mortality in patients with CAD and 
high cholesterol level. Furthermore, CARE trial 
reported that statins’ cardio-protective effects were 
also present in myocardial infarction patients with 
average cholesterol levels.11 Those two studies showed 
that the beneficial effects of statins in coronary artery 
disease were independent of the cholesterol levels. 
This evidence is supported by another study, Anglo-
Scandinavian Cardiac Outcomes Trial Lipid-Lowering 
Arm (ASCOT-LLA),12,13 which showed that the 
cardiovascular benefit of Atorvastatin was present in 
average and low cholesterol level. The follow-up of this 
trial also showed that statins’ cardiovascular benefits are 
still present eleven years afterwards (Figure 3).
Aspirin, a non-steroidal anti-inflammatory 
drug, which acts as an anti-platelet in cardiovascular 
disease management, also plays a role in secondary 
prevention of atherosclerotic CVD. It is responsible for 
maintaining blood flow in CAD by inhibiting platelet 
aggregation process that occurs during and after a 
plaque rupture in myocardial infarction (MI) patients. 
In 2002, Anti-thrombotic Trialists Collaboration 
reported that aspirin reduced the risk of vascular events 
in patients with acute and prior CVDs (myocardial 
infarction and stroke).4,14,15 Aspirin is also used 
routinely after revascularisation procedure because 
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percutaneous coronary intervention (PCI) procedure 
often causes local vascular injuries that disrupt the 
endothelial layer and trigger the haemostatic process. 
These micro-injuries are prone to thrombosis and 
often results in myocardial ischemia post-PCI.4 In 
PCI procedure; aspirin is usually combined with 
either secondary anti-platelet drugs (i.e., Ticlopidine, 
dipyridamole, clopidogrel) or anti-coagulants (i.e. 
warfarin). Regardless of the combinations of aspirin, 
there is a significant decrease in acute complications 
of PCI and reduction in thirty days mortality post-
PCI.4
Moreover, the benefits of aspirin may also be 
achieved in patients post coronary bypass surgery 
(CABG).4 The 5% to 15% risk of graft occlusion due 
to thrombosis at the anastomotic site can be prevented 
by aspirin administration immediate after the surgery. 
Continued aspirin administration for one year after 
bypass surgery reduces the rate of occlusive events more 
than 50%.4 However, increased perioperative bleeding 
complications should be noticed and considered before 
aspirin administration in both PCI and CABG.  
Role of statins and aspirin in primary 
prevention of ASCVD
As mentioned in the previous section, although the 
roles of statins and aspirin in secondary prevention of 
CVD are well established, ASCVD remains challenging. 
Now, the enthusiasm for statins and aspirin as primary 
prevention modalities has been developed. 
Cardiovascular risk assessments in 
ASCVD
Nowadays, ASCVD risk assessment becomes an 
important issue because people want to predict 
their cardiovascular events risk in the next few 
years. Subsequently, this CV risk can be used as a 
basis for starting cardiovascular primary prevention 
programmes, including lifestyle modification, healthy 
diet and administration of certain drugs, such as statins 
and aspirin. Three most common CV risk calculators 
are QRISK2 from NICE, Framingham point scores 
from National Heart, Lung, and Blood Institute 
(NHLBI) and SCORE from European Society of 
Cardiology (ESC).16,17,18-20 They use several parameters 
such as age, gender, body mass index (BMI), smoking 
behaviour, blood pressure and cholesterol level to 
measure the CV risk in the next ten years. It should 
be noted that not all medical conditions are suitable 
for CV risk assessment using these scores. For 
example, NICE did not recommend the use of CV 
risk calculator (QRISK2) in several conditions such 
as Type-1 Diabetes, people with eGFR less than 60 
ml/min/1.73m2 (chronic kidney disease/CKD) with/
without albuminuria, familial hypercholesterolemia 
and pre-existing CVD.29 
Statins in primary prevention of 
ASCVD
The role of statins in primary prevention of CVD 
is controversial. The Cholesterol Treatment Trialist 
(CTT) Collaboration evaluated data from 27 
clinical studies of statins for primary and secondary 
prevention of CVD and reported that per 1 mmol/L 
reduction in LDL-C, there was approximately 20% 
risk reduction for major cardiovascular events. These 
advantageous effects were seen irrespective to the 
gender, cardiovascular disease risk, diabetic status, 
cholesterol level and age.21,22 Additionally, a Cochrane 
systematic review of 18 trials of statins in primary 
prevention of CVD reported that statins lowered 
cardiovascular events risk by 27% even though in the 
group of patients with statins, the risk of getting type-2 
diabetes is increased approximately 9%.21
Other large studies also showed the benefits 
of statins in primary prevention setting. They are 
ASCOT-LLA and JUPITER trial that reported a 
marked reduction in CV risk after administration 
of statins. As mentioned in the previous section, in 
ASCOT-LLA trial, there were reductions in CV risks 
in hypertensive patients without prior CV events 
regardless of the LDL cholesterol level.12 In JUPITER 
trial, the trial was stopped after a median follow-up 
of 1.9 years (of maximum 5 years) because of a 44% 
reduction in all vascular events, 54% reduction in MI 
risk, 48% reduction in stroke and 20% reduction in 
all-cause mortality.23,24  
In the JUPITER trial and most of other trials that 
evaluated the role of statins in the primary prevention 
setting of CVD, there were no significant differences 
between the treatment groups with placebo regarding 
the serious adverse events. Additionally, there was no 
difference among treatment groups with regards to 
the occurrence of muscle weakness, myopathy and 
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hepato-renal impairment. JUPITER trial also reported 
a significant reduction in cancer mortality in a short-
term period of observation (1.9 years). However, as 
well as other studies (Figure 4), JUPITER trial also 
reported a few incidents of diabetes with a small 
increase in HbA1c.23,24 
Aspirin in primary prevention of ASCVD
The benefits of aspirin in the primary prevention 
setting are also debatable. A few years ago, there were 
two large randomised trials of aspirin for primary 
prevention of CVD, Physician Health Study and 
British Physician Study.4 The Physician Health Study 
randomised subject between 40 and 84 years and 
treated them with either aspirin 325 mg or placebo. 
This study was stopped after 5-years follow-up period 
because of significant results, such as 44% reduction 
in the risk of MI. However, there was no reduction 
in CV-related mortality.4 In contrast, the British 
Physician study reported no difference in the incidence 
of MI. Additionally, it also reported that there was 
no difference in CV-related mortality after six years 
of aspirin treatment and there was an increase in the 
incidence of haemorrhagic stroke.4  
In 1994, Antiplatelet Trialists Collaboration 
reported that there was a significant reduction in 
vascular and all-cause mortality in patients with 
increased risk of occlusive CVDs, such as patients with 
stable angina, valvular heart diseases, atrial fibrillation 
and peripheral artery diseases. Furthermore, compared 
to these benefits, the risk of major non-fatal and fatal 
bleeds was quite small.4,14,25 Additionally, these results 
were significant in all groups of patients irrespective of 
gender, age and the presence of comorbidities such as 
hypertension and diabetes. In 1998, another study, the 
Thrombosis Prevention Trial, also tried to look up the 
effects of aspirin in high-risk individuals. The results 
were 20% reduction in ischemic heart disease events 
in aspirin-groups after 6-years follow-up without any 
significant effect on total mortality. However, aspirin 
alone did not cause any increase in the incidence of 
stroke.26,27 
Older adults have a higher risk of getting CV events 
and may represent an age-group in which aspirin could 
provide the biggest benefits, but at the same time, older 
adults are very vulnerable to major haemorrhages, 
such as haemorrhagic stroke and gastrointestinal 
bleeding.28 However, in the latest trial (AAA trial, 
2010), it was reported that there was no CV benefit 
of using aspirin in primary prevention and there was 
an increasing trend of disabling stroke. Another study 
(ASPREE study) was commenced to resolve this issue 
and the result will be available in 2017. In this study, 
they evaluate the 5-years risk of having major CV 
events, dementia, cancer and cognitive impairment 
and measure the composite endpoint of disability in 
older population.28
Bleeding risks of aspirin, including haemor-
rhagic stroke, are important issues to be resolved. 
However, more importantly, the reason the latest 
aspirin prevention studies in high-risk populations 
did not show any CV-related events Relative Risk 
(RR) reduction is probably because of the attenu-
ation of the effect of aspirin in these populations. 
Firstly, in high-risk populations, they often use 
statins and ACE-inhibitor that have already had 
some antithrombotic and anti-inflammatory effects. 
In this population, the effectiveness of aspirin as an 
antithrombotic agent is reduced. Secondly, diabetes 
in high-risk population is quite common and this 
condition may lead to the aspirin resistance. Thirdly, 
the hypothesis that the limited platelet inhibition 
by aspirin may be mediated by increasing weight, 
drug interactions and ageing process.28 All of these 
complexities make the decision to use aspirin in the 
primary prevention setting even more challenging 
because the benefits of aspirin are likely to be out-
weighed by the harms.  
C 
Figure 4. The Effects of statins therapy and incidence of 
diabetes in placebo-control trials. Almost all of the trials 
reported hazard ratio (HR) more than one regarding diabetes 
incidence in statin administration (cited from: Ridker PM, 
Pradhan A, MacFayden JG, et al. Circ Cardiovasc Qual 
Outcomes. 2009;2:279-85).
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Figure 5. A timeline of trials of aspirin in primary prevention conducted between 1988-
2010 (cited from: Ward SA, Demos L, Workman B, et al. Drugs Aging. 2012;29(4)).
Discussions
Statins and aspirin are two common drugs in 
cardiovascular disease management. Their roles in acute 
and secondary prevention setting are well established. 
Statins have a lipid lowering activity and some 
pleiotropic effects beyond it. Aspirin has a powerful 
anti-platelet activity that is beneficial in many major 
cardiovascular events. However, as mentioned in the 
previous section that the use of both drugs in primary 
prevention setting is controversial. Statins’ controversy 
is more trivial than aspirins’ because all of the studies 
reported the same benefit of statins in CV risk reduction. 
The dilemma of statins administration is mainly in 
diabetics and patients with chronic kidney disease. 
However, all studies of aspirin in primary prevention of 
cardiovascular disease did not report the same results. 
Some of them reported benefits without any harms, 
some of them reported benefits with a few incidents of 
harms and some of them reported no benefit at all with 
enormous potential harms (Figure 5).
Those complexities lead to difficulties in making 
recommendations for these drugs in primary 
prevention setting. In 2014, National Institute for 
Health and Care Excellence (NICE) published its 
new guideline about statins in primary prevention.29 
It recommended that the decision to start statin 
therapy should be made after a discussion about the 
risks and benefits of the treatment with regards to 
the potential benefits of lifestyle modifications and 
other modifiable risk factors managements. Regarding 
ineffective lifestyle modifications, statin treatment 
is initiated after the risk assessment. Atorvastatin 
20 mg is administered to the person who has a 10% 
or greater 10-year risk of developing CVD (using 
QRISK2). Consequently, for people more than 85 
years, statins may be beneficial in reducing nonfatal 
MI risk. In diabetic persons, NICE divided the 
recommendation according to the type of diabetes. 
In type-1 diabetes, statins are considered for all 
patients who are above 40 years old or have diabetes 
for more than a decade, have established nephropathy 
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or have other CVD risk factors. However, in type-2 
diabetes, statins are limited only in patients with 
10% or greater 10-year CVD risk. Additionally, there 
is a particular recommendation for CKD patients 
as well.29 ESC evaluated this issue from a slightly 
different aspect. Its recommendation is based on two 
parameters, such as total CV risk (using SCORE) 
and LDL-C levels.16-18 Despite the difference in the 
parameter; both recommendations agreed that statin 
therapy should be started in high-risk patients. 
The recommendation of aspirin in primary 
prevention is more controversial than statins’. In 2015, 
NICE published a new guideline on this issue.31 It did 
not recommend any routine prescription of antiplatelet 
drugs for primary prevention of CVD. However, 
some experts recommend treatment with aspirin for 
people with hypertension and have at least one of two 
conditions, such as people with age above 50 years with 
high cardiovascular disease risk (10-year cardiovascular 
disease risk more than 20%) or have an impaired renal 
function. In this group of patients, aspirin should 
not be started before the blood pressure is less than 
150/90 mmHg to reduce the bleeding risk. In non-
hypertensive patients with low CVD risk, aspirin is not 
recommended because there is evidence that aspirin 
increases the risk of severe bleeding. Recently, NICE 
recommendation of aspirin for diabetic patients was re-
evaluated due to three meta-analyses that had reported 
no strong benefit of aspirin in primary prevention of 
cardiovascular disease in diabetes.31 
In 2012, ESC also advised considering aspirin for 
primary prevention of cardiovascular disease in people 
with hypertension who have impaired renal function, 
or are at high CV risk (20-30% major CV events in the 
next ten years).18,31 However, ESC did not recommend 
aspirin to be used in individuals without cardiovascular 
or cerebrovascular disease due to the increased risk of 
bleeding (Class III, LOE B).18 
Conclusion
Statins and aspirin are very beneficial in cardiovascular 
disease managements. However, the use of these 
drugs in primary prevention setting still needs further 
research. So far, statins in primary prevention are 
recommended only under certain conditions (i.e. high-
risk people). The use of aspirin in primary prevention 
is more limited and controversial because the potential 
harms outweigh the benefits of this drug. Finally, larger 
and more comprehensive clinical trials are needed to 
resolve these efficacy-safety related issues. 
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